Tirzepatide is a drug licensed by the US Food and Drug Administration, used to treat type 2 diabetes, and sold under the trade name “Mounjaro’ The study was conducted by researchers led by Dr. Satish Garg from the University of Colorado Denver, and was published in the journal Diabetes Technology & Therapeutics on March 20.
The researchers found a significant decrease in body mass index (BMI) and weight in the first group compared to the second group. They also found a decrease in HbA1c as early as three months.